Apricus Biosciences (APRI) Unit Signs Vitaros Marketing Agreement for Germany
Tweet
Share
E-mailGet Alerts APRI Hot Sheet
Join SI Premium – FREE
Apricus Biosciences, Inc. (Nasdaq: APRI) reports that its wholly-owned subsidiary NexMed(USA), Inc. has signed with Sandoz, a division of Novartis (NYSE: NVS), an exclusive collaboration for Germany to market Apricus Bio's Vitaros® drug for the treatment of erectile dysfunction.
Pursuant to the collaboration, Sandoz will pay Apricus Bio up to €21 million – divided into a fixed upfront payment and specific regulatory and commercial milestones – as well as, double digit royalties on net sales. Total upfront and milestone payments represent approximately $28 million based on today's exchange rate.
Pursuant to the collaboration, Sandoz will pay Apricus Bio up to €21 million – divided into a fixed upfront payment and specific regulatory and commercial milestones – as well as, double digit royalties on net sales. Total upfront and milestone payments represent approximately $28 million based on today's exchange rate.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novartis (NVS) Announces FDA Approval of Lutathera
- Novartis (NVS) PT Raised to $116 at BMO Capital
- Altamira Therapeutics (CYTO) Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
